{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:35:23Z","timestamp":1765546523121,"version":"3.37.3"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,12,8]],"date-time":"2019-12-08T00:00:00Z","timestamp":1575763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["T32HS026133"],"award-info":[{"award-number":["T32HS026133"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP160674"],"award-info":[{"award-number":["RP160674"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA039192"],"award-info":[{"award-number":["R01DA039192"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Given concerns about suboptimal pain management for actively treated cancer patients following the 2014 federal reclassification of hydrocodone, we examined changes in patterns of opioid prescribing among surgical breast cancer patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Data from a large nationally representative commercial health insurance program from 2009 to 2017 were used to identify women aged 18\u2009years and older who were diagnosed with carcinoma in-situ or malignant breast cancer and received breast-conserving surgery or mastectomy from 2010 to 2016. Generalized linear mixed models were used to estimate the adjusted odds ratio (aOR) for receipt of \u22651-day, &amp;gt;30-day, or \u2265\u200990-day supply of opioids in the 12 months following surgery adjusting for demographics, cancer treatment\u2013related characteristics, and preoperative opioid use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 60,080 patients were included in the study. Surgically treated breast cancer patients in 2015 (aOR = 0.90, 0.84\u20130.97) and 2016 (aOR = 0.80, 0.74\u20130.86) were less likely to receive \u22651-day supply of opioid prescriptions when compared with patients in 2013. Patients who had surgery in 2015 (aOR = 0.89, 0.81\u20130.98) and 2016 (aOR = 0.80, 0.73\u20130.87) were also less likely to receive &amp;gt;30-day supply of prescription opioids in the 12 months following surgery. However, only surgical breast cancer patients in 2016 were less likely to receive \u226590-day supply (aOR = 0.86, 0.76\u20130.98).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Surgically treated breast cancer patients are less likely to receive short- and long-term opioid prescriptions following the implementation of hydrocodone rescheduling. Further studies on the potential impact of federal policy on cancer patient pain management are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0758","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T19:25:15Z","timestamp":1575487515000},"page":"281-289","source":"Crossref","is-referenced-by-count":6,"title":["Opioid Prescribing Trends in Women Following Mastectomy or Breast-Conserving Surgery Before and After the 2014 Federal Reclassification of Hydrocodone"],"prefix":"10.1093","volume":"25","author":[{"given":"Derrick C.","family":"Gibson","sequence":"first","affiliation":[{"name":"Department of Preventive Medicine and Population Health, University of Texas Medical Branch \u2013 Galveston, Galveston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Na","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Population Health, University of Texas Medical Branch \u2013 Galveston, Galveston, Texas, USA"},{"name":"Office of Biostatistics, University of Texas Medical Branch \u2013 Galveston, Galveston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukaila A.","family":"Raji","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Geriatrics, University of Texas Medical Branch \u2013 Galveston, Galveston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques G.","family":"Baillargeon","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Population Health, University of Texas Medical Branch \u2013 Galveston, Galveston, Texas, USA"},{"name":"Office of Biostatistics, University of Texas Medical Branch \u2013 Galveston, Galveston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Fang","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Population Health, University of Texas Medical Branch \u2013 Galveston, Galveston, Texas, USA"},{"name":"Office of Biostatistics, University of Texas Medical Branch \u2013 Galveston, Galveston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,12,8]]},"reference":[{"key":"2021122510224727600_R1","first-page":"49661","article-title":"Schedules of controlled substances: Rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule","volume":"79","author":"Drug Enforcement Administration","year":"2014","journal-title":"Fed Regist"},{"key":"2021122510224727600_R2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/pds.4376","article-title":"Decline in opioid prescribing after federal rescheduling of hydrocodone products","volume":"27","author":"Raji","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021122510224727600_R3","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/jgs.15332","article-title":"Opioid prescriptions in older Medicare beneficiaries after the 2014 federal rescheduling of hydrocodone products","volume":"66","author":"Kuo","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"2021122510224727600_R4","first-page":"532","article-title":"The effect of a federal controlled substance act schedule change on hydrocodone combination products claims in a Medicaid population","volume":"23","author":"Tran","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2021122510224727600_R5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamainternmed.2015.7799","article-title":"Effect of US Drug Enforcement Administration's rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing","volume":"176","author":"Jones","year":"2016","journal-title":"JAMA Intern Med"},{"year":"2017","author":"Optum: Clinformatics Data Mart","key":"2021122510224727600_R6"},{"key":"2021122510224727600_R7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/jgs.15945","article-title":"Long-term opioid therapy in older cancer survivors: A retrospective cohort study","volume":"67","author":"Shah","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"2021122510224727600_R8","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"2021122510224727600_R9","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"year":"2019","author":"Centers for Medicare and Medicaid Services","key":"2021122510224727600_R10"},{"key":"2021122510224727600_R11","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.ajem.2016.09.002","article-title":"Has the rescheduling of hydrocodone changed ED prescribing practices?","volume":"34","author":"Oehler","year":"2016","journal-title":"Am J Emerg Med"},{"key":"2021122510224727600_R12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/08998280.2016.11929431","article-title":"Change in prescription habits after federal rescheduling of hydrocodone combination products","volume":"29","author":"Seago","year":"2016","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"2021122510224727600_R13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jemermed.2016.08.026","article-title":"Decreased opioid prescribing in a pediatric emergency department after the rescheduling of hydrocodone","volume":"52","author":"Chumpitazi","year":"2017","journal-title":"J Emerg Med"},{"key":"2021122510224727600_R14","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"key":"2021122510224727600_R15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.7326\/M18-1243","article-title":"Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention's 2016 Opioid Guideline","volume":"169","author":"Bohnert","year":"2018","journal-title":"Ann Intern Med"},{"author":"National Conference of State Legislatures","key":"2021122510224727600_R16"},{"key":"2021122510224727600_R17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamasurg.2018.2651","article-title":"Association of hydrocodone schedule change with opioid prescriptions following surgery","volume":"153","author":"Habbouche","year":"2018","journal-title":"JAMA Surg"},{"key":"2021122510224727600_R18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jpainsymman.2017.12.368","article-title":"Assessing opioid stigma in oncology outpatients receiving palliative care for cancer-related pain (S714)","volume":"55","author":"Kollas","year":"2018","journal-title":"J Pain Symptom Manage"},{"key":"2021122510224727600_R19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/SLA.0000000000001993","article-title":"Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures","volume":"265","author":"Hill","year":"2017","journal-title":"Ann Surg"},{"key":"2021122510224727600_R20","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/SLA.0000000000002365","article-title":"Wide variation and overprescription of opioids after elective surgery","volume":"266","author":"Thiels","year":"2017","journal-title":"Ann Surg"},{"key":"2021122510224727600_R21","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1245\/s10434-019-07542-1","article-title":"Reducing narcotic prescriptions in breast surgery patients: A prospective analysis","volume":"26","author":"Fan","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"2021122510224727600_R22","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1056\/NEJMc1905045","article-title":"Statewide implementation of postoperative opioid prescribing guidelines","volume":"381","author":"Vu","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122510224727600_R23","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2017.74.1363","article-title":"New persistent opioid use among patients with cancer after curative-intent surgery","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0758","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0758","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/4\/281\/41920197\/oncolo_25_4_281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/4\/281\/41920197\/oncolo_25_4_281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:23:24Z","timestamp":1640427804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/4\/281\/6443363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,8]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,12,8]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0758","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2020,4,1]]},"published":{"date-parts":[[2019,12,8]]}}}